Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults

Vaccine

Volumn 21, Issue 27-30, 2003, Pages 4234-4237

  Frey, Sharon ^a   Poland, Gregory ^b   Percell, Sandra ^c   Podda, Audino ^d  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d CHIRON VACCINES   (Italy)

Author keywords

FLUAD ; Fluzone ; MF59 adjuvanted influenza vaccine

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE;

ADULT; ANALGESIA; ARTHRALGIA; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEVER; FOLLOW UP; HEADACHE; HEALTH STATUS; HEAT; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; INFLUENZA; INFLUENZA VACCINATION; INJECTION; INJECTION SITE; MALAISE; MULTICENTER STUDY; MYALGIA; NAUSEA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE;

EID: 0348078310     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00456-0     Document Type: Article

References (6)

1. Barker W.H., Mullooly J.P. Impact of epidemic type A influenza in a defined adult population. Am. J. Epidemiol. 112:1980;798-811.
2. Barker W.H. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States. Am. J. Pub. Health. 76:1986;761-765.
3. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 19:2001;2673-2680.
4. Dowdle W.R., Coleman M.T., Mostow S.R., Kaye H.S., Schoenbaum S.C. Inactivated influenza vaccine. Part 2. Laboratory indices of protection. Postgrad. Med. J. 49:1973;159-163.
5. Nicholson K.G., Colegate A.E., Podda A.et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomized trial of two potential vaccines against H5N1 influenza. Lancet. 357:2001;1937-1943.
6. Iorio AM, Francisci D, Camilloni B, et al. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunized with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active anti-retroviral therapy. Vaccine 2003;21:3629-37.